Skip to main content
Evidence Snapshot

Protein Tat

CHEMBL4011 SINGLE PROTEIN Human immunodeficiency virus type 1 group M subtype B (isolate HXB2)(HIV-1)
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T12:51:04Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL4011
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Protein Tat as ChEMBL target CHEMBL4011, mapped to UniProt P04608. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Protein Tat
SINGLE PROTEIN · Human immunodeficiency virus type 1 group M subtype B (isolate HXB2)(HIV-1)
As of 2026-09-13
ChEMBL target ID
CHEMBL4011
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P04608
Protein Tat
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Protein Tat matters

As of 2026-09-13

Protein Tat is reviewed as Protein Tat (UniProt P04608); Protein Tat shows clinical signal disease relevance led by HIV infection.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 3 approved drugs, 1120 compounds, and 38 assays, with lead potency reaching pChEMBL 6.9.

Disease context
HIV infection

Protein Tat shows clinical signal disease relevance led by HIV infection. 1 linked drug keep the rationale reviewable. Linked drugs include RO-24-7429.

Start review with HIV infection because it currently carries clinical signal support. Linked drugs include RO-24-7429. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Clinical signal 1 linked drug
Activity base
Portfolio and assay base

ChEMBL currently tracks 3 approved drugs, 1120 compounds, and 38 assays for this target. The dominant activity type is IC50. CHEMBL483254 is the current potency anchor at pChEMBL 6.9.

Use CHEMBL483254 as the tractability anchor when discussing potency (pChEMBL 6.9).

Activity source · ChEMBL 36 via Core Engine
3 approved pChEMBL 6.9
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Protein Tat matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P04608, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why HIV infection is currently treated as clinical signal support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

1120
Total Compounds
38
Total Assays
3
Approved Drugs
IC50: 998.0, EC50: 119.0, KD: 7.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL483254
 6.9 EC50 Approved
No preferred name
CHEMBL343448
 6.7 EC50 Approved
No preferred name
CHEMBL4526214
 6.1 EC50 —
No preferred name
CHEMBL4446565
 6.0 EC50 —
No preferred name
CHEMBL1075826
 6.0 IC50 —

Approved Drugs

Structure Compound First Approval
PANOBINOSTAT
CHEMBL483254
 2015
ROMIDEPSIN
CHEMBL343448
 2009
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T12:51:04Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL4011